|
1）Kanwar YS, Wada J, Sun L, et al. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med (Maywood). 2008; 233: 4-11
|
|
|
|
2）Hink U, Li H, Mollnau H, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res. 2001; 88: E14-22
|
|
|
|
|
|
3）Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev. 2001; 22: 36-52
|
|
|
|
|
|
4）Pahakis MY, Kosky JR, Dull RO, et al. The role of endothelial glycocalyx components in mechanotransduction of fluid shear stress. Biochem Biophys Res Commun. 2007; 355: 228-33
|
|
|
|
|
|
5）Dane MJ, Khairoun M, Lee DH, et al. Association of kidney function with changes in the endothelial surface layer. Clin J Am Soc Nephrol. 2014; 9: 698-704
|
|
|
|
|
|
6）Nieuwdorp M, Mooij HL, Kroon J, et al. Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes. 2006; 55: 1127-32
|
|
|
|
|
|
7）Kuwabara A, Satoh M, Tomita N, et al. Deterioration of glomerular endothelial surface layer induced by oxidative stress is implicated in altered permeability of macromolecules in Zucker fatty rats. Diabetologia. 2010; 53: 2056-65
|
|
|
|
|
|
8）Satoh M, Kobayashi S, Kuwabara A, et al. In vivo visualization of glomerular microcirculation and hyperfiltration in streptozotocin-induced diabetic rats. Microcirculation. 2010; 17: 103-12
|
|
|
|
|
|
9）Friden V, Oveland E, Tenstad O, et al. The glomerular endothelial cell coat is essential for glomerular filtration. Kidney Int. 2011; 79: 1322-30
|
|
|
|
|
|
10）Salmon AH, Ferguson JK, Burford JL, et al. Loss of the endothelial glycocalyx links albuminuria and vascular dysfunction. J Am Soc Nephrol. 2012; 23: 1339-50
|
|
|
|
|
|
11）Salmon AH, Satchell SC. Endothelial glycocalyx dysfunction in disease: albuminuria and increased microvascular permeability. J Pathol. 2012; 226: 562-74
|
|
|
|
|
|
12）Singh A, Ramnath RD, Foster RR, et al. Reactive oxygen species modulate the barrier function of the human glomerular endothelial glycocalyx. PLoS One. 2013; 8: e55852
|
|
|
|
|
|
13）van den Hoven MJ, Rops AL, Bakker MA, et al. Increased expression of heparanase in overt diabetic nephropathy. Kidney Int. 2006; 70: 2100-8
|
|
|
|
|
|
14）Wijnhoven TJ, van den Hoven MJ, Ding H, et al. Heparanase induces a differential loss of heparan sulphate domains in overt diabetic nephropathy. Diabetologia. 2008; 51: 372-82
|
|
|
|
|
|
15）van den Hoven MJ, Wijnhoven TJ, Li JP, et al. Reduction of anionic sites in the glomerular basement membrane by heparanase does not lead to proteinuria. Kidney Int. 2008; 73: 278-87
|
|
|
|
|
|
16）Gil N, Goldberg R, Neuman T, et al. Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes. 2012; 61: 208-16
|
|
|
|
|
|
17）Zatz R, Dunn BR, Meyer TW, et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest. 1986; 77: 1925-30
|
|
|
|
|
|
18）Satchell SC, Braet F. Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier. Am J Physiol Renal Physiol. 2009; 296: F947-56
|
|
|
|
|
|
19）Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int. 2008; 74: 22-36
|
|
|
|
|
|
20）Weil EJ, Lemley KV, Mason CC, et al. Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy. Kidney Int. 2012; 82: 1010-7
|
|
|
|
|
|
21）Toyoda M, Najafian B, Kim Y, et al. Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes. 2007; 56: 2155-60
|
|
|
|
|
|
22）Nakagawa T, Sato W, Glushakova O, et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol. 2007; 18: 539-50
|
|
|
|
|
|
23）Nakayama T, Sato W, Kosugi T, et al. Endothelial injury due to eNOS deficiency accelerates the progression of chronic renal disease in the mouse. Am J Physiol Renal Physiol. 2009; 296: F317-27
|
|
|
|
|
|
24）Sun YB, Qu X, Zhang X, et al. Glomerular endothelial cell injury and damage precedes that of podocytes in adriamycin-induced nephropathy. PLoS One. 2013; 8: e55027
|
|
|
|
|
|
25）Yuen DA, Stead BE, Zhang Y, et al. eNOS deficiency predisposes podocytes to injury in diabetes. J Am Soc Nephrol. 2012; 23: 1810-23
|
|
|
|
|
|
26）Isermann B, Vinnikov IA, Madhusudhan T, et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med. 2007; 13: 1349-58
|
|
|
|
|
|
27）Bock F, Shahzad K, Wang H, et al. Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc. Proc Natl Acad Sci U S A. 2013; 110: 648-53
|
|
|
|
|
|
28）Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008; 358: 1129-36
|
|
|
|
|
|
29）Sivaskandarajah GA, Jeansson M, Maezawa Y, et al. Vegfa protects the glomerular microvasculature in diabetes. Diabetes. 2012; 61: 2958-66
|
|
|
|
|
|
30）Daehn I, Casalena G, Zhang T, et al. Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis. J Clin Invest. 2014; 124: 1608-21
|
|
|
|
|
|
31）de Zeeuw D, Coll B, Andress D, et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephro-pathy. J Am Soc Nephrol. 2014; 25: 1083-93
|
|
|
|
|
|
32）Bohle A, Wehrmann M, Bogenschutz O, et al. The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis. Pathol Res Pract. 1991; 187: 251-9
|
|
|
|
|
|
33）Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006; 17: 17-25
|
|
|
|
|
|
34）Tasnim F, Zink D. Cross talk between primary human renal tubular cells and endothelial cells in cocultures. Am J Physiol Renal Physiol. 2012; 302: F1055-62
|
|
|
|
|
|
35）Zeisberg EM, Potenta SE, Sugimoto H, et al. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol. 2008; 19: 2282-7
|
|
|
|
|
|
36）Li J, Qu X, Bertram JF. Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice. Am J Pathol. 2009; 175: 1380-8
|
|
|
|
|
|
37）He J, Xu Y, Koya D, et al. Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease. Clin Exp Nephrol. 2013; 17: 488-97
|
|
|
|
|
38）Castoldi G, di Gioia CR, Bombardi C, et al. Renal antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats. Am J Nephrol. 2013; 37: 65-73
|
|
|
|
|
|
39）Kanasaki K, Shi S, Kanasaki M, et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes. 2014; 63: 2120-31
|
|
|
|
|
|
40）Hirata K, Shikata K, Matsuda M, et al. Increased expression of selectins in kidneys of patients with diabetic nephropathy. Diabetologia. 1998; 41: 185-92
|
|
|
|
|
|
41）Seron D, Cameron JS, Haskard DO. Expression of VCAM-1 in the normal and diseased kidney. Nephrol Dial Transplant. 1991; 6: 917-22
|
|
|
|
|
|
42）Okada S, Shikata K, Matsuda M, et al. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes. 2003; 52: 2586-93
|
|
|
|
|
|
43）Cheng H, Wang H, Fan X, et al. Improvement of endothelial nitric oxide synthase activity retards the progression of diabetic nephropathy in db/db mice. Kidney Int. 2012; 82: 1176-83
|
|
|
|
|
|
44）Satoh M, Fujimoto S, Haruna Y, et al. NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol. 2005; 288: F1144-52
|
|
|
|
|
|
45）Kidokoro K, Satoh M, Channon KM, et al. Maintenance of endothelial guanosine triphosphate cyclohydrolase I ameliorates diabetic nephropathy. J Am Soc Nephrol. 2013; 24: 1139-50
|
|
|
|
|
|
46）Li H, Forstermann U. Uncoupling of endothelial NO synthase in atherosclerosis and vascular disease. Curr Opin Pharmacol. 2013; 13: 161-7
|
|
|
|
|
|
47）Morris SM, Jr., Gao T, Cooper TK, et al. Arginase-2 mediates diabetic renal injury. Diabetes. 2011; 60: 3015-22
|
|
|
|
|
|
48）You H, Gao T, Cooper TK, et al. Arginase inhibition mediates renal tissue protection in diabetic nephropathy by a nitric oxide synthase 3-dependent mechanism. Kidney Int. 2013; 84: 1189-97
|
|
|
|
|
|
49）Ogawa S, Nakayama K, Nakayama M, et al. Methylglyoxal is a predictor in type 2 diabetic patients of intima-media thickening and elevation of blood pressure. Hypertension. 2010; 56: 471-6
|
|
|
|
|
|
50）Giacco F, Du X, D’Agati VD, et al. Knockdown of glyoxalase 1 mimics diabetic nephropathy in nondiabetic mice. Diabetes. 2014; 63: 291-9
|
|
|
|
|
|
51）Brouwers O, Niessen PM, Miyata T, et al. Glyoxalase-1 overexpression reduces endothelial dysfunction and attenuates early renal impairment in a rat model of diabetes. Diabetologia. 2014; 57: 224-35
|
|
|
|
|
|
52）Jo-Watanabe A, Ohse T, Nishimatsu H, et al. Glyoxalase I reduces glycative and oxidative stress and prevents age-related endothelial dysfunction through modulation of endothelial nitric oxide synthase phosphorylation. Aging Cell. 2014; 13: 519-28
|
|
|
|
|